Author pages are created from data sourced from our academic publisher partnerships and public sources.
Dynamics of clonal evolution in myelodysplastic syndromes
- H. Makishima, T. Yoshizato, +34 authors J. Maciejewski
- Biology, Medicine
- Nature Genetics
- 1 February 2017
To elucidate differential roles of mutations in myelodysplastic syndromes (MDS), we investigated clonal dynamics using whole-exome and/or targeted sequencing of 699 patients, of whom 122 were… Expand
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review
Edoxaban, an oral direct inhibitor of factor Xa, was recently approved in the United States and Japan for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation… Expand
Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma.
Inhibitors of the mammalian target of rapamycin (mTOR) have entered the landscape of treatment for advanced RCC. Their development has been based on their unique biology and their potential to… Expand
mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
OBJECTIVES The mechanistic (mammalian) targets of rapamycin (mTOR) inhibitors with known growth Inhibitory effect are currently in clinical trial for treatment of human cancer. The aim of this review… Expand
STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.
Large granular lymphocyte leukemia (LGL) is often associated with immune cytopenias and can cooccur in the context of aplastic anemia (AA) and myelodysplastic syndromes (MDS). We took advantage of… Expand
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
- Y. Saunthararajah, M. Sekeres, +21 authors J. Maciejewski
- The Journal of clinical investigation
- 2 March 2015
BACKGROUND Mutational inactivation in cancer of key apoptotic pathway components, such as TP53/p53, undermines cytotoxic therapies that aim to increase apoptosis. Accordingly, TP53 mutations are… Expand
Identification of a carboxyl-terminal motif essential for the targeting of Na+-HCO-3 cotransporter NBC1 to the basolateral membrane.
- H. C. Li, R. T. Worrell, +5 authors M. Soleimani
- Medicine, Biology
- The Journal of biological chemistry
- 8 October 2004
The Na+-HCO3- cotransporter NBC1 is located exclusively on the basolateral membrane and mediates vectorial transport of bicarbonate in a number of epithelia, including kidney and pancreas. To… Expand
Novel Recurrent Mutations in the Ras-Like GTP-Binding Gene Rit1 in Myeloid Malignancies
Abstract 558 In addition to chromosomal and epigenetic abnormalities, somatic mutations constitute key pathogenic lesions in myeloid neoplasms. Individual somatic mutations or various combinations… Expand
Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B
- H. Husseinzadeh, T. Chiasakul, +6 authors A. Cuker
- Haemophilia : the official journal of the World…
- 1 March 2018
Cerebral microbleeds (CMBs) represent clinically silent haemorrhagic events. Cerebral microbleeds (CMBs) portend negative neurovascular and cognitive outcomes in the general population and are… Expand
Molecular Predictors Of Response To Lenalidomide In Myeloid Malignancies
Lenalidomide (LEN) is effective in alleviating anemia in patients with MDS. Patients with del5q show particularly good responsiveness to LEN, but this drug has a significant activity in MDS patients… Expand